|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||
  AddictionVolume 98 Issue 11, Pages 1625 - 1632 Published Online: 23 Oct 2003 Journal compilation © 2010 Society for the Study of Addiction Published on behalf of the Society for the Study of Addiction
Abstract | References | Full Text: HTML, PDF (Size: 114K) | Related Articles | Citation Tracking  RESEARCH REPORT Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study Copyright 2003 Society for the Study of Addiction to Alcohol and Other Drugs KEYWORDS Cocaine • opioids • tiagabine • methadone • pharmacotherapy • clinical trial ABSTRACTAims We sought to evaluate the safety and efficacy of the GABAergic agent tiagabine in reducing cocaine use among methadone-treated patients. Design Ten-week randomized double-blind placebo-controlled trial. Setting Opiate Treatment Research Program, Veteran's Affairs Connecticut Healthcare System in West Haven, Connecticut, USA. Participants The participants were 45 cocaine-dependent methadone-treated patients who were predominately Caucasian (75.6%), male (77.8%) and never married (53%) with an average age of 38 years (SD = 6.5). Interventions Comparison groups received tiagabine 12 mg/day (n = 15), tiagabine 24 mg/day (n = 15) or placebo (n = 15). Measures Baseline assessments included the Structured Clinical Interview for DSM-IV, the Addiction Severity Index, a urine drug test, self-reported use and opiate withdrawal scales. Urine drug tests were performed thrice weekly. Findings Treatment retention was over 80% for all treatment groups. The sample mean (± SE) of cocaine-free urines for the first week after study entry and before tiagabine was started was 1.16 (0.19) urines/week. During weeks 9 and 10 cocaine-free urines increased significantly from baseline by 33% with high-dose tiagabine (24 mg/day), by 14% with low-dose tiagabine (12 mg/day) and decreased by 10% with placebo (hierarchical linear model, Z= 2.03; P < 0.05). Self-reported cocaine use also decreased significantly more with active medications than with placebo. Conclusions Tiagabine at 24 mg/day was well tolerated among these methadone-treated patients with only one reporting headache. Tiagabine appears to be a promising GABAergic medication that moderately improves cocaine-free urines. Submitted 9 December 2002;
| 
|
